Post Hoc Your Way To A Better Future: Neurocrine Will Build On Troubled Tardive Dyskinesia Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Deviant results at one of eight clinical sites led the company to exclude data from seven out of 32 trial subjects in a post-hoc analysis of a Phase IIa study of its VMAT2 inhibitor that will lead to closer monitoring in the later phases of the development program.